On March 18, 2025, Milestone Pharmaceuticals Inc. entered into an amended agreement allowing them to sell up to $77.8 million in common shares, increasing from the previous $50 million limit. The sales will be managed by Jefferies LLC, with a commission of 3% on sales made.